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Abstract
The purpose of this research is to identify and explore effective supply chain
management principles as mitigating measures to improve contingency pharmaceutical
item shortfalls in the Air Force Medical Service Contingency Pharmaceutical Program.
Analysis of current pharmaceutical shortages demonstrates a significant trend of
insufficient demand signals for various pharmaceutical items, resulting in instances of
non-fulfillment by private sector suppliers.
Through the scope of transaction cost economics, a cost-benefit analysis for
various alternatives was conducted. The proposed alternatives evaluated in this thesis
include continuation of the status quo, centralized procurement models from a single site,
and procurement from regionally designated ordering sites.
This research clearly shows that consolidating demand of shortage items across
Active Duty War Reserve Material assemblages, though applications of centralized
purchasing principles that leverage prime vendor contract fill rates, can lead to substantial
increases in material availability at costs that justify the calculated benefits.
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STRATEGIC SOURCING OF AIR FORCE CONTINGENCY
PHARMACEUTICALS: A COST-BENEFIT ANALYSIS APPROACH
I. Introduction
Background
Forecasts for the year 2020 project that supply chain expenses will become the
largest expenditure for U.S. healthcare organizations, commanding more budgetary
requirements than the previous top expense of labor (Paavola, 2019). This means that the
materials which allow a healthcare facility to function could now attract more attention
than the medical professionals who provide the actual service of healthcare. At the same
time, organizations are experiencing increasing costs across the entire spectrum of
healthcare provision which are further cutting into profit margins (Paavola, 2019). In a
strategic effort to increase performance outcomes, organizations are shifting focus to the
improvement of supply chain management as an efficiency driver. This information has
healthcare leaders focusing on practices and policies to extract value and minimize waste
from supply chain practices. Practices such as demand aggregation through group
purchase organizations, efficient data processing and analysis, and item standardization
have garnered attention of the biggest healthcare companies in the country in an effort to
improve supply chain operations (Michigan State University, 2019).
This research takes the strategic supply chain focus found in the private sector,
and applies lessons learned to make Air Force Medical Service (AFMS) operations more
effective. Therefore, the purpose of this research is to identify, evaluate, and apply
optimal supply chain efforts to address shortages in the Air Force Contingency
Pharmaceutical Program. Analysis of current contingency pharmaceutical shortages
1

shows a significant trend of insufficient, individual site demand signals for various
pharmaceutical items, resulting in non-fulfillment by private sector suppliers. This
research applies a cost-benefit analysis to evaluate various alternatives through the
theoretical scope of transaction cost economics. As a result, this research clearly shows
that consolidating the demand of shortage items across Active Duty War Reserve
Material (AD WRM) assemblages, though applications of centralized purchasing
principles that leverage prime vendor contract fill rates, can lead to substantial increases
in material availability for pharmaceutical items.
The AFMS currently manages a $1.3 billion contingency medical program
comprised of over 5,100 assemblages across the globe at 87 unique locations (JMAR,
2019). According to the Air Force Medical Logistics Guide, this program supports the
capabilities of medical units in contingency situations such as home station medical
response, deployments, and humanitarian efforts (AFMOA/SGAL, 2017). A critical
element of contingency medical assemblages are pharmaceutical items, which account
for over $113 million of the program (JMAR, 2019). A crucial subset of the overarching
contingency medical program, and a primary focus of this research, are AD WRM
assemblages. These assemblages are durable and transportable kits that provide necessary
medical items, including medical supplies, equipment, and pharmaceuticals to
accomplish deployment or mobility objectives (AFMOA/SGAL, 2017). Pharmaceutical
items, as a component of AD WRM assemblages, experience high turnover due to
consumption or expiration, as items routinely have a shelf life of only 24 to 36 months
(AFMRA MLD, 2019). As a result from an enterprise-level, the Air Force Medical
Readiness Agency (AFMRA), Medical Logistics Readiness Support Branch, has
2

observed shortages in material availability for many of these pharmaceutical items
(AFMRA MLD, 2019).
Problem Statement
Over 35 percent of all Air Force contingency medical assemblages, and 21
percent of AD WRM material assemblages, do not meet deployment requirement
thresholds as defined by AFMAN 41-209 (JMAR, 2019). Deployment thresholds
according to this guidance require a minimum of 90 percent material availability of
commodity items contained in the assemblage (U.S. Air Force, 2019). A major driver of
this shortfall is the inability to readily procure contingency pharmaceutical items, which
account for 41 percent of all contingency item shortages across the entire contingency
pharmaceutical program (JMAR, 2019). Due to the unpredictable nature of contingency
operations many contingency pharmaceutical items have non-recurring or non-usage
demands, compared to Medical Treatment Facility (MTF) day-to-day pharmaceutical
demands which have established and frequent usage patterns that result from supporting a
relatively predictable healthcare environment (AFRMA MLD, 2019). This ambiguity in
demand leads to order rejections for contingency items as Department of Defense (DoD)
contracted distributors are only obligated to fulfill items which have established usage
demands (Defense Logistics Agency, 2013).
This contractual condition leaves the AFMS at a disadvantage in developing and
maintaining adequate inventories to support current and future requirements, which could
occur with the onset of contingency operations. According to the 2016 Defense Logistics
Agency (DLA) Medical Supply Chain report, DoD pharmaceutical item purchases
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through DLA Troop Support make up only 1 percent of the entire U.S. pharmaceutical
industries’ market share (Defense Logistics Agency, 2016). For this reason, the Air
Force, as a DoD component, must ensure that demand signals for contingency items are
as robust as possible to ensure adequate supply for required inventories. Ultimately,
inefficiencies and shortfalls of contingency item supply chains could directly impact our
Nations’ readiness in military and humanitarian operations.
Purpose Statement
The purpose and primary goal of this analysis is to identify and explore effective
supply chain principles, through the theory of transaction cost economics, as mitigation
measures to improve current contingency pharmaceutical item shortfalls in the AFMS
program. Through these approaches the resulting analysis will inform leaders about
possible mitigation efforts, and their inherent costs and benefits, in an effort to remedy
shortfalls in contingency pharmaceutical procurement methods.
Research Questions
RQ 1: Are there strategic supply chain integration efforts that can be employed to remedy
current shortfalls?
RQ 2: What are the costs and benefits of possible strategic supply chain integration
efforts?
Research Focus
First, the theoretical scope of transaction cost economics is reviewed to build the
research foundation to conduct an assessment of contingency item procurement
processes. The literature review also evaluates current contingency medical procurement
4

processes, introduces the concept of cost-benefit analysis, and highlights principles of
strategic sourcing and demand aggregation. Subsequently, the data collection practices of
this research and methodological applications of cost-benefit analyses are outlined.
Lastly, findings are presented with a discussion on research limitations and areas for
future research.
Methodology
The methodology utilized to gather information and present the findings of this
research is a cost-benefit analysis. The cost-benefit analysis conducted in this thesis was
influenced by the framework outlined in the text, Cost-Benefit Analysis: Concepts and
Practice.
Assumptions
The main assumption of this thesis is that the AFMS will maximize use of the
established DLA Pharmaceutical Prime Vendor (PPV) contracts to the fullest extent
possible to procure needed contingency items. Demand, in terms of this research will be
the current contingency pharmaceutical item shortages for each location. The DLA PPV
contract defines a usage item as a pharmaceutical that is, “ordered by the ordering facility
a minimum of once per month for a minimum quantity of one and is in the Medical
Master Catalog (MMC). Usage data shall be provided by the customer during the
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implementation period and will be reviewed by the customer and the PPV periodically”
(Defense Logistics Agency, 2013, p. 41).
This thesis also applies the fact that all Air Force ordering stock record ordering
locations are designated as Master Ordering Facilities (MOFs) under the PPV contract.
These MOFs are authorized to order under the PPV contract for external DoD customers
(Defense Logistics Agency, 2013). With this designation applied to AFMS ordering
units, the centralized and regionalized ordering facilities, identified in the constructed
alternatives, can set up delivery locations at external sites, given they are in the same
geographical region (Defense Logistics Agency, 2013). This effort would minimize
transportation expenses as there are no distribution fees for all MOF orders according to
the PPV contract (Defense Logistics Agency, 2013). Lastly, ordering sites located in the
Upper Prairie region will fall under the West region for demand aggregation, ordering,
and resulting distribution of shortage items due to their proximity to the West region.
Limitations
The scope of this research focused specifically on the 120 AD WRM deployable
unit type code allowance standards, shown in Appendix A. Therefore, the programs of
Home Station Medical Response (HSMR), Force Health Protection (FHP), Mass
Casualty First Aid Kits, and MAJCOM specific programs were not evaluated in this
research. Also, this research did not include and in-depth evaluation or shortage
remediation of non-pharmaceutical contingency items, including contingency medical
equipment, repair, or supply items. Lastly, other military services’ contingency
pharmaceutical items, ordering policies, or budgetary information was not assessed in
6

this evaluation. These separate contingency commodity items and other service
component programs will be addressed in the future research section of this thesis.

7

II. Literature Review
Chapter Overview
The purpose of this chapter is to provide the foundational knowledge used to support
the decision of aggregating demand for shortage items across the enterprise in an effort to
implement centralized procurement practices. This chapter begins with an evaluation of
transaction cost economics theory. This topic will provide the theoretical foundation for
the assessment of contingency item procurement purchasing processes.
This literature review will then highlight the various policies and regulations that
form and govern the current processes in AFMS contingency item procurement. Through
review of these methods, a concise and consolidated process will be outlined from the
planning stage to the execution phase. This chapter also introduces the concepts and
outlines the steps of a cost-benefit analysis. Lastly, supply chain principles of strategic
sourcing are fully evaluated. The strategic sourcing component applied in this thesis is
the concept of implementing centralized purchasing structures through practice of
demand and purchasing aggregation to establish sufficient usage data for contingency
pharmaceutical items.
Transaction Cost Economics
The review of applicable literature and theory for this research begins with a
description of transaction cost economics. The basic premise of transaction cost
economics theory instantiates that individuals or firms seek to make the best possible
decisions for their organization. This theory holds that organizations select certain
products, goods, or services over alternatives due to the economization, optimization, or
8

minimization of transaction costs (Williamson, 1979). In transaction cost economics
theory, the unit of analysis is the singular transaction (Williamson, 2010). A transaction
in this theory is defined as an economic exchange of a good or service from a provider to
a separate user (Pint and Baldwin, 1997). Transaction costs can arise from a litany of
organizational functions and actions, including sourcing selections, contract management,
and performance measurements (Pint and Baldwin, 1997).
Since organizations usually operate in resource-constrained environments, it is
paramount that they make economically efficient decisions in charting future financial
and operational decisions (Mahoney and Ketokivi, 2015). As the AFMS is not immune to
this prevalence of constrained operating environments, their business practices are highly
suitable for evaluation through a scope of transaction cost economics. Limited budgets,
constraints on contracting and purchasing avenues, and the unpredictable nature of
military operations fuel the often constrained environment of Air Force procurement.
These decisions in constrained environments can range from organizational structure
constructs, personnel configuration, or purchasing efforts; however, all focus on a key
idea of managing relationships and transactions to minimize waste while simultaneously
creating value (Mahoney and Ketokivi, 2015).
Throughout the evaluation of transaction cost economics, the theme of bounded
rationality emerges as a key concept. Bounded rationality implies that there are limits to
time, control, and information throughout a system, which can result in suboptimal
decisions, actions, and organizational principles (Pint and Baldwin, 1997). This means
that entities of the system, including employees, processes, and agreements, may engage
in or promote suboptimal behavior, that can be detrimental to effective decision making
9

in operations (Pint and Baldwin, 1997). Bounded rationality is not a result of
incompetence or inability, but rather a product of the fact that humans have limitations
that influence actions and strategy (Williamson, 2010). Williamson (2010) describes that
humans are limited in their rationality due to complexities found in the business
environment. Transaction cost economics suggests that when the resulting effects of
bounded rationality greatly influence organizational transactions, organizational
integration efforts could be used to ensure the value of transactions are captured (Pint and
Baldwin, 1997). This concept of integration, through the implementation of centralized
procurement procedures, will be further evaluated in this literature review.
Contingency Item Purchasing Processes and Shortfalls
There are undoubtedly various transaction costs associated with the procurement
of contingency pharmaceuticals, but before the minimization of these costs and
maximization of value can be pursued, the initial processes of contingency item demand,
outlined in Appendix B, must be evaluated. The initial step of the planning process
begins at the operational planning (OPLAN) level where Combatant Commanders’
capability requirements for medical assets are defined and transferred to the Air Force
Surgeon General’s (AF/SG) Office (HQ USAF/SG, 2013). These resulting OPLANs lay
out requirements for medical necessities in contingency instances such as number and
types of beds based on projected casualty streams, number of personnel deployed in the
area and aeromedical evacuation projections (AFMRA/SG4M, 2019). From these
OPLAN requirements, the AF/SG publishes the Medical Planning and Programing
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Guidance (MPPG) to determine future endeavors in contingency planning (HQ
USAF/SG, 2013).
The MPPG, as the Air Force Medical community’s planning and programming
guidance document, ultimately determines the bottom up requirements to support medical
program priorities, such as WRM, in support of combatant commander requirements (HQ
USAF/SG, 2013). The process for putting the AF/SG vision, as outlined by the MPPG,
into action is the Readiness Requirements Planning and Resourcing Process (RRPR). In
the RRPR medical unit type code requirements are identified for these major OPLANs,
which creates the total demand list (TDL) (HQ USAF/SG, 2013). The TDL is the
resulting product of the RRPR that captures all combatant commander requirements, thus
establishing the demand for the system (HQ USAF/SG, 2013). The establishment of the
TDL, from the origins of the various OPLANs, concludes the planning phase of
contingency item procurement. Execution of this process begins with the Medical
Requirements List (MRL).
The MRL is a conglomeration of all AFMS possible personnel and equipment
assignments, mission requirements, and expansion capabilities (HQ USAF/SG, 2013).
Ultimately, this listing outlines where each required capability, as defined by the TDL,
will be stationed and in what fiscal year the capability will be required (HQ USAF/SG,
2013). Once requirements are distributed amongst Air Force locations, via the MRL,
assemblages are constructed, supported, and replenished at dictated sites through
established procurement channels, including the Pharmaceutical Prime Vendor (PPV)
contract.

11

The PPV contract, awarded through DLA, is the primary mechanism exercised for
procuring contingency pharmaceutical items. The contract was awarded in 2014 and
consists of one 30 month base period and three 30 month option periods, available
through 2024 (Defense Logistics Agency Troop Support, 2019). In Fiscal Year (FY) 19,
the breakdown of contingency pharmaceutical purchases shows utilization of the PPV
contract over 70 percent of the time in pharmaceutical procurement actions (JMAR,
2019). According to DLA, fulfillment rates for the PPV contract typically range from 9598 percent (Defense Logistics Agency Troop Support, 2019). This generalization was
substantiated by obtaining access to information from the fill rate module managed by
DLA. The average fill rate for the FY19 was 96.19 percent (“Fill Rate Application”,
2019).
This fill rate percentage will be used as a factor in the cost-benefit analysis
methodology to calculate remedied shortage amounts. According to the contract
statement of work, “The PPV program provides worldwide support to DoD customers
[…] by providing pharmaceutical and pharmaceutical related products. The PPV will
provide War Readiness Material (WRM) support” (Defense Logistics Agency, 2013, p.
31). After solicitation, the contract was awarded to Amerisource Bergin Drug
Corporation (ABC), designating them as the primary supplier of pharmaceutical
contingency items to the DoD (Defense Logistics Agency Troop Support, 2019). ABC
services both CONUS and OCONUS contingency pharmaceutical demands from its
nearly 30 U.S. distribution centers (Amerisource Bergin, 2015). All geographical regions
are serviced by ABC, with the exception of the states of South Dakota, North Dakota, and
Minnesota. These states are serviced by the Dakota Drug Company under the designation
12

of the Upper Prairie Region through a separately awarded small business contract
(Defense Logistics Agency Support, 2019).
Under the current contract, the primary supplier must maintain a fill rate of 98
percent for all orders predicated upon sufficient usage demands (Defense Logistics
Agency, 2013). This distinction is highly important, as it identifies that the fill rate will
only be inclusive of products which meet usage requirements. Usage under the contract is
defined as an item, “ordered by the ordering facility a minimum of once per month for a
minimum quantity of one and is in the Medical Master Catalog (MMC). Usage data shall
be provided by the customer” (Defense Logistics Agency, 2013, p. 40). With the
shortcomings discussed above through the PPV contracts, it is clear that additional
mitigating measures must be evaluated to address current system issues.
Cost-benefit Analysis
A cost-benefit analysis is a methodology for accurately assessing policies or projects
based on their associated impacts, in terms of benefits and costs, that are valued in
monetary terms (Boardman, Greenberg, Vining, and Weimer, 2011). Cost-benefit
analyses are a common evaluation tool in military environments used to shape national
security, set acquisition policies, and direct investments in service and supply
procurement (Melese, Richter, and Soloman, 2015). According to Boardman et al.
(2011), there are three types of cost-benefit analyses, including ex-ante, in medias res,
and ex-post. Ex-ante analyses evaluate new initiatives that could possibly be
implemented in the future (Boardman et al., 2011). In medias res analyses are actually
conducted during the life of a current project, while ex-post analyses are completed after
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a project has been completed or retired (Boardman et al., 2011). The current contingency
pharmaceutical procurement program, supported primarily through the DLA PPV
contract, will be analyzed through an in medias res cost-benefit analysis as the contract is
still valid with options for continuation through 2024 (Defense Logistics Agency, 2013).
In looking outside of the scope of current contracting vehicles, the findings of this costbenefit analysis could also provide useful insight for future solicitations of DoD
contingency item contracts.
An in medias res cost-benefit analysis can be accomplished through navigation of the
following steps: specification of alternative projects, identification of project
stakeholders, determination of costs and benefits, quantitative prediction of impacts over
the life of the project, monetization of impacts, discounting of benefits to obtain present
values, computation of the present value of each alternative, sensitivity analysis, and
crafting of final recommendations (Boardman et al., 2011). For the purposes of this
research, as the data provided encompasses single year contingency pharmaceutical
procurement values, the steps of monetization of impacts, discounting of benefits to
obtain present values, and computation of the final present values will be compressed into
a single step designated as monetization. The resulting steps are illustrated below and will
be used as this research’s methodological framework to evaluate and compare alternative
actions.
1) Alternative Projects

2) Stakeholder
Identification

3) Determination
of Impacts

4) Impact
Prediction

5) Monetezation

Figure 1. Cost-Benefit Analysis Process (Boardman et al., 2011)
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6) Sensitivity
Analysis

7)
Recommendation

The first step of the cost-benefit analysis is to clearly identify all possible options that
could be undertaken in the given environment. In this first step of identifying alternative
projects, the wide array of possible options must be defined and limited, as in most cases,
there are a large number of viable options (Boardman et al. 2011). Within this set of
alternatives, the current status quo, or instance of no change, should also be fully
evaluated. Status quo information is needed to compare the current project to
hypothesized options to determine if a new course of action, with its associated costs and
efforts, should even be attempted (Boardman et al., 2011). In the methodology section,
the status quo and possible alternative actions, with varying applications of centralized
procurement, are defined.
Following the definition of alternatives stakeholders need to be properly identified.
Identification of these stakeholders can be difficult to delineate and scope down to a
relevant level for the given analysis being undertaken (Boardman et al., 2011). Projects
can often be analyzed from a focused level excluding higher level or external
stakeholders who may have a more global perspective (Boardman et al., 2011).
Therefore, it is critical to evaluate possible stakeholders fully and then scope based on the
level of connection to the project. In the AFMS contingency procurement model, certain
benefits, as well as costs, could be felt at a local base level; however, there are likely
additional costs and benefits that are realized at the enterprise level. Once all relevant
stakeholders of the project are identified and informed, the costs and benefits of the
project must be evaluated.
Evaluating the costs and benefits of a project are first done by identifying the physical
impact categories of the possible alternatives (Boardman et al., 2011). The term impacts
15

include the inputs and outputs of a project, which are then cataloged as either a cost or a
benefit to the project (Boardman et al., 2011). Boardman et al. (2011) provides a
framework of identifying a cause and effect relationship between physical outcomes of
the project and the affected parties. If there is a correlation between stakeholder action
and outcome of the system, there is likely an impact category that can be identified as a
benefit or a cost (Boardman et al., 2011). These resulting benefits and costs then need to
be measured in some form of units. The method for measuring each impact is usually
based upon the data from which the project is evaluated (Boardman et al., 2011). This
means if there is monetary information, the resulting impacts will likely be measured in
increased profit or cost avoidance; however, there are many ways that impacts can be
measured, including time savings or operational efficiency improvements (Boardman et
al. 2011).
After impacts have been identified, the task is to then predict the impacts over the life
of the project (Boardman et al., 2011). Based on the calculated costs and benefits, the
analyst needs to tie the impacts to a quantifiable output. The purpose of a cost-benefit
analysis is to assess alternative courses of action which require prediction of outcomes
supported by accurate data (Boardman et al., 2011). The methodology section of this
research will apply data analysis of current information to predict impacts of different
project implementations. Benefits resulting from changing processes, compared to
current operations, can be analyzed through the in media res cost-benefit analysis.
Once cost and benefit predictions are established, it is important to assign monetary
values in order to effectively compare outcomes as options may have differing costs and
benefits that cannot be compared on a direct unit level. Effectively monetizing values can
16

allow for interpretation and comparison of results as it gives differing impacts similar
units (Boardman et al., 2011). In some cases it is relatively simple to apply a monetary
value to an impact, such as instances of cost avoidance; however, in many occurrences
these monetary evaluations are not easily constructed. This is especially true in the
military or defense environment.
In these instances where monetization is not straight forward, Boardman et al. (2011)
advocates for avoiding reinvention of established practices through the use of plug in or
estimated values when available. There is no silver bullet in connecting resulting outputs,
such as increased material availability, with quantitative, economic inputs, such as money
spent. However, a mechanism for quantifying the resulting impacts in military or defense
situations is proposed in the military production function, which attempts to quantify
defense outputs based on monetary inputs (Hartley and Soloman, 2015). According to
Hartley and Soloman (2015) “Defense outputs involve a complex set of variables
concerned with security, protection and risk management […] unlike private markets
there are no precise benefit measures for defense output” (p. 44). Inputs, such as cost of
procurement, are more easily identified and measured than resulting outputs, which in
this research is material availability of contingency pharmaceutical items (Hartley and
Soloman, 2015).
Therefore a cost-benefit analysis acts as a starting point to, “to identify the costs of
defense and then ask whether defense provides at least a comparable level of benefits in
the outputs produced” (Hartley and Soloman, 2015, p. 65). The methodology of this
research will provide an estimated ratio that attempts to quantify the level of benefits, in
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the terms of increased material availability, to the economic inputs, in terms of
programmatic appropriations.
After monetary values have been established for various impacts to the different
project sets, uncertainties of the process must be evaluated through sensitivity analysis.
Utilizing sensitivity analysis allows users to evaluate possible what-if scenarios.
Identifying possible outcomes can increase confidence in analysis, or help to identify
areas for further evaluation to refine conclusions bolstered upon the conducted analysis
(Georgiev, 2015). Sensitivity analysis can be conducted in numerous manners, all ranging
in complexity and accuracy. The sensitivity analysis methods that will be used in this
research are partial sensitivity analysis, which looks at how benefits change when a single
assumption is varied while holding other aspects constant, and maximum and minimum
case sensitivity analysis, which looks at the impact to benefits when the most or least
favorable assumptions are applied (Boardman et al., 2011).
Once sufficient sensitivity analysis has been completed, the analyst can then make a
recommendation based on the project with the largest present value (Boardman et al.,
2011). It is important to remember that final present values are established from estimates
of impacts and their resulting monetary values (Boardman et al., 2011). In many
instances, specifically in the military, there are multiple variables, with different weights,
that can lead to the selection of one project over another. This means that that completion
of a cost-benefit analysis is only one input to the entire decision making process. There
are often other contributing, and sometimes conflicting, factors such as politics, security,
or legal requirements that can greatly influence final decisions (Boardman et al., 2011).
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Strategic Sourcing - Centralized Purchasing through Demand Aggregation
The items that companies or governments procure are purchased to create value as
a factor in production or meeting organizational requirements (Tate, Fawcett, Schoenherr,
Ashenbaum, Carter, and Bals, 2016). Given that firms are in most cases required to make
purchases to assist in their value creation proposition, strategic decisions must be made
on how purchasing will be conducted throughout the organization. In alignment with the
theory of transaction cost economics, “Given the considerable volume of resources
involved, firms and governments always seek to optimize procurement so as to deliver
value […] In pursuing such a goal often the first important decision is to choose between
centralized and decentralized purchasing” (Dimitri, Gustavo, and Giancarlo, 2006, p. 47).
Purchasing from a firm or organization perspective can take various shapes and is a
strategic decision that must be made to maximize value of the system as a whole.
The three main purchasing systems include centralized, decentralized, and hybrid
purchasing models (Dimitri et al., 2006). In a centralized purchasing model, decisions of
organizational procurement including determinations of what products to buy, how to
best navigate procurement channels, and when to make purchases are managed by a
single entity in the organization (Dimitri et al., 2006). Advantages of centralized
procurement structures include large scale aggregation of requirements, reductions in
effort duplication, and more effective supply strategies (Tate et al., 2016).
In a fully decentralized procurement model, purchases for the organization are
dispersed amongst different entities, who make more localized decisions of how, what
and when to make acquisitions (Dimitri, 2006). Although this research supports
movement away from the full decentralization of purchases, there are inherent benefits to
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this purchasing structure. Decentralization of purchasing can be more responsive to the
local units desires and allow for a better understanding of local requirements (Tate et al.,
2016). The third type of procurement systems are hybrid models. In a hybrid purchasing
model, purchasing decisions are made both centrally and locally depending on situational
factors (Dimitri et al., 2006). In this structure, units can either make localized purchases,
or communicate demand and spending information to a centralized purchasing unit that
can look for aggregation opportunities leading to better fulfillment and cost savings (Tate
et al., 2016).
Before the turn of the century, companies in many cases made strategic decisions
to give individual business units more independence in terms of purchasing decisions
(Rozemeijer, van Weele, and Weggeman, 2003). With the shift in increased competition
in the business environment, these firms are now undergoing consolidation processes in
their purchasing strategies as they are recognizing the benefits of pooling common
requirements (Rozemeijer et al., 2003). Organizations are now exhibiting this shift in a
transition to hybrid purchasing structures with centralized features that leverage sourcing
benefits of the entire organization’s demand portfolio (Trautmann, Bals, and Hartmann,
2009).
A challenge of implementing hybrid practices is clearly defining purchasing
boundaries and policies. These boundaries involve determining which facets will fall
under the authority of a centralized purchasing location to maximize organizational wide
synergies and which facets of the organization will exercise local procurement
(Trautmann et al., 2009). If organizations are able to overcome the challenges inherent to
implementing more hybridized purchasing structures, there are numerous benefits. A
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main benefit of harnessing the capabilities of hybrid purchasing organizations are
purchasing synergies. Purchasing synergies are defined as resulting value from the
combination of multiple business units’ resources, information, and knowledge in
purchasing (Trautmann et al., 2009).
A relevant example of purchasing synergies currently exhibited in the healthcare
industry, are Group Purchasing Organizations (GPO). Demand aggregation practices are
widely applied and utilized in the health care industry through GPOs. A GPO is an
established entity that healthcare facilities or networks can join to purchase supplies,
pharmaceuticals, and equipment. Joining the GPO leverages centralized procurement
benefits, because the GPO consolidates demand from all users and captures the savings
and efficiency of the larger volume; however, purchases are still made at the hospital or
health network level under the GPO agreements (Dobson, Heath, Reuter, and DaVanzo,
2014). There are numerous benefits to procuring healthcare items through a GPO, such as
greater economies of scale, volume purchasing, increased negotiating power and reduced
administrative costs (Dobson et al., 2014). The increased economies of scale and volume
purchasing result from the consolidation of various entities’ demand for like items, which
ultimately reduces transaction costs. Due to the benefits of GPOs, it is estimated that
between 96 and 98 percent of U.S. Hospitals utilize GPO’s in their procurement mix
(Dobson et al., 2014).
As discussed previously in the medical contingency procurement process, the Air
Force primarily obtains items through the DLA established PPV contract. The purchasing
of required items for each location, based on requirements, is done on a site by site basis
at the 87 separate stock record account number locations. These accounts do contain a
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mix of other sub accounts, within their portfolio, however they are still ordered and
maintained at the main location. For example, Wright Patterson Air Force Base supports
20 organizations assigned under their account. Of these 20 accounts, 19 are ordered from
and physically located at Wright Patterson Air Force Base. Contingency items are
maintained at the primary location and only sent to external locations if required (WPMC
WRM, 2019). Therefore, this procurement system operates in a decentralized manner,
with 87 main locations, shown in Appendix C, reporting demand to distributors to obtain
pharmaceutical items for their site. The research and findings of this research will provide
justification for the recommendation of transitioning to a model that maintains the local
sites’ abilities to procure more standard use items through government contracts at their
own discretion, while harnessing the power of centralized purchasing models through
demand aggregation to remedy contingency item shortages in the Air Force.
Relevant Research
AFMRA/SG4M utilizes an established reporting mechanism, the Air Force
Shortage Summary Report, to identify and designate the service’s top contingency
pharmaceutical item shortages. Shortage rankings are designated using an algorithm that
accounts for the criticality designation of items, individual material availability
percentages, and assemblage instances with current shortages (JMAR, 2019).
Initial analysis of these top shortage items, identified on a per item basis in
Appendix D and site aggregated basis in Figure 2, clearly demonstrated a pattern of
insufficient site demand profiles correlated with top shortage items. The figure below is
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highly skewed to the left, which signifies the preponderance of insufficient, or small,
demand signals for identified items, ultimately resulting in shortages.

Figure 2. Aggregated Top 20 Contingency Pharmaceutical Items (JMAR, 2019)

Through aggregation of the top ten shortage items, 306 instances of item demand
were identified. Of the 306 demand instances, 157 (51%) have usage demand profiles of
less than one item per month. Expanding the pool to the top 20 shortage items shows an
increasing pattern of 466 demand instances, with 288 occurrences (62%) registering a
demand of less than one item per month. These sample sets of the program helped
identify the core issue, insufficient demand signals dispersed across various locations
leading to instances of shortages, for further analysis. The methodology and results will
attempt to show how aggregating these small demand profiles will allow the Air Force to
strategically reduce contingency item shortages.
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Summary
The theory of transaction cost economics, with its robust theoretical history and
application in today’s economic environment, is the optimal theory on which to base this
thesis and resulting cost-benefit analysis. It is clear that although there have been
programmatic efforts to minimize contingency item shortages that there is still room for
systematic improvement. The application of strategic sourcing, through leveraging the
strengths of decentralized and centralized purchasing models, is tried and tested as shown
by recent business research and findings.
In the next chapter, the methodology, will describe the avenues and methods for
data collection and examination used to build the cost-benefit analysis of this thesis.
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III. Methodology
Chapter Overview
The purpose of this chapter is to describe the primary data source and outline the
construction of the model. The purpose of the model will describe the current situation
and calculate relevant values such as shortage by location, acquisition costs, and
transportation costs. The resulting data from the constructed model will then be utilized
to initiate the cost-benefit analysis of this thesis.
Data Collection and Model Construction
The primary data source for this cost-benefit analysis is the Joint Medical Asset
Repository (JMAR). According to the Defense Health Agency, JMAR is, “a web-enabled
repository that captures inventory and transactions from distributed medical logistics
systems at over 400 locations and provides flexible reporting on materiel inventory,
status, movement and location” (Defense Health Agency, 2018). This data repository
breaks down contingency medical assets by service component and allows for a thorough
analysis of the current AFMS Contingency Pharmaceutical Program, with the granularity
to drill down to individual locations and assemblage component items. Other pertinent
information was gathered from the Medical Contingency Requirements Workflow
(MCRW) and AFMRA Medical Requirements List (MRL). Through integrations of raw
data and generated reports from these platforms, the current state of the AFMS
Contingency Pharmaceutical Program can be illustrated. The compiled data shows that
the AD WRM program is made of 2,533 assemblages, 21 percent of which do not meet
AFMAN 41-209 deployment requirements (JMAR, 2019). These assemblages are
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programmed for 827K pharmaceutical items to meet demand requirements (JMAR,
2019). Of these 827K items, there is a shortage of 159K items across 61 locations,
resulting in a material availability of 80.7 percent.
After depicting the current pharmaceutical item shortages in the AD WRM portfolio,
the model for this research was constructed. Pharmaceutical items shortages were
aggregated based on the item’s prime equivalent (PE) identification number, evaluated
for PPV contract availability, and lastly assessed for minimum usage thresholds. Upon
completion of this evaluation there were 646 unique pharmaceutical items that exhibited
sufficient usage demand upon aggregation (JMAR, 2019). Ultimately, the purpose of this
model construction is to establish all pertinent information necessary to conduct the costs
benefit analysis.
Cost-benefit Analysis Application
The cost-benefit analysis of this thesis will follow the prescribed steps outlined in
the literature review. Steps one through three of the cost-benefit analysis fall under the
methodology portion of this thesis, while steps four through seven will be conducted in
the subsequent analysis and conclusion sections.
In the first step of the cost-benefit analysis, four alternative projects were defined.
The alternative projects to be assessed in this research are: continuation of the status quo,
centralized purchasing at a single site, centralized purchasing at a single site for U.S.
regions, and lastly, purchasing at various regional sites. The status quo is included as an
alternative to act as a benchmark to determine if any resulting action should be taken in
an attempt to improve the system. Alternative 1 assesses the current situation at sites with
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AD WRM shortages. In this alternative there will be no proposed changes to
consolidation of demand and sites will continue to procure items on an individual basis.

Figure 3. Alternative 1 Network (DLA Troop Support, 2016)

Alternative 2 identifies system wide level shortage aggregation opportunities from
a single designated site to fulfill both U.S. and international site shortages. The site
selected for this central hub was Kelly Field in San Antonio, Texas. When analyzing
aggregated demand for each site, Kelly Field had the largest aggregated shortage amount
of pharmaceutical items (JMAR, 2019).
Through centralization at Kelly Field, transportation instances would be
minimized and the current consolidated storage and deployment center (CSDC) mission
of Kelly Field best suits the demands of receiving, handling, and transporting large
numbers of contingency medical items (Whitson, 2013).
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Figure 4. Alternative 2 Network (DLA Troop Support, 2016)

Alternative 3 mirrors the strategy and processes of alternative 2, but eliminates
fulfillment of international region areas in an effort to assess changes in fulfillment and
transportation costs based on the smaller distribution network. The thought process
behind this change was that the network could still capture the aggregated demand
profiles of the sites in the U.S. regions, while eliminating the international shipping costs
that are required to ship procured items from Kelly Field to various OCONUS locations.
This process will still identify system wide level shortage aggregation
opportunities at a single designated site, but only for the U.S. PPV regions of West,
South, and North. The centralized ordering site for this action will remain at Kelly Field
for the same justifications outlined in alternative 2.
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Figure 5. Alternative 3 Network (DLA Troop Support, 2016)

Lastly, the fourth alternative identifies global shortage aggregation opportunities
at regionally designated sites. The sites selected for these regional hubs were designated
by the Prime Vendor regional delineations of West, South, North, Pacific, and Europe
(Defense Logistics Agency, 2013). In evaluating aggregated demand, the location with
largest aggregated shortage amounts for each region were Travis AFB (West), McGuire
AFB (North), Kelly Field (South), Kadena AB (Pacific), and Ramstein AB (Europe).
Through centralized purchasing at these locations resulting transportation occurrences
would be minimized as these ordering locations already have the highest regional demand
when compared to peers.
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Figure 6. Alternative 4 Network (DLA Troop Support, 2016)

Once alternative projects are fully defined, in the second step of the cost-benefit
analysis stakeholders need to be identified to ensure no relevant desires and limitations
are overlooked. Although the identification of stakeholders in this cost-benefit analysis
will not directly influence the calculated costs, it is important to identify these
stakeholders from a systems perspective. Starting at the most micro level, the first
stakeholder would be the local account managing the various assemblages assigned to
their unit under the MRL. It is important to understand that there will be relatively
incalculable individual transaction costs at this localized level from the various
coordination that will take place. This research accounts for these resulting transaction
costs as fixed costs, as work would be done under the current WRM service contract.
From the next stakeholder level, the higher headquarters or AFMRA level, these
local transaction costs may not be realized, but it is important to understand that
enactment of any of these alternative projects will likely place additional workload on the
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individual units. At the higher headquarters level, there will need to be communication
and guidance with the sites conducting the centralized ordering in the form of what items
are need to be ordered, when orders need to be placed and, when items need to be
distributed to the demanding locations.
Following the construction of alternative actions and stakeholder delineation, step
three of the cost-benefit analysis outlines the costs and benefits of the project. Relevant
costs to be assessed in this analysis include acquisition costs of procuring shortage items
and transportation costs of shipping the procured items from the centralized ordering site
to the demanding site. Acquisition cost as an impact to this cost-benefit analysis will be
calculated by aggregating the shortage of each item to first determine the amount
required. Once the shortage amount of each pharmaceutical item is determined, the
acquisition cost is determined by multiplying the remedied shortage amount by the cost
per unit established by the PPV contract.
Individual item weight information is maintained in the Medical Contingency
Requirements Workflow (MCRW) portal. Weights, in pound increments, were gathered
for each of the shortage items to establish a baseline estimate for total weight shipped in
each alternative project. The average weight of the assessed items was 2.6 pounds, which
was conservatively rounded up to 3 pounds for shipping cost calculations. Shipping costs
for three pound shipments were then gathered from third party logistics (3PL) companies
FedEx and DHL. These 3PL companies are the current Air Force shipping intermediaries
for contingency pharmaceutical items. Estimated shipping rates used to calculate
transportation costs were established by gathering shipping quotations for 3 pound
shipments from Kelly Field to each unique site. From the 60 unique shipping quotations,
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it was determined that the average domestic shipping cost was $12.02 for a three pound
shipment and the average international shipping cost was $103.94 for a three pound
shipment (JMAR, 2019). These values were then proportionally applied to the breakdown
of anticipated domestic and international shipping amounts, which were 72 percent and
28 percent of shipments, respectively (JMAR, 2019).
This resulted in an estimated 3 pound shipping rate of $37.30. This calculation of
$37.30 per shipment is conservative in nature because shipping costs from the 3PL
companies are not directly linear when looking at pound increments. This means that a 3
pound domestic shipment, costing roughly $12.02, would not jump to $24.02 for a
shipment of 6 pounds. In fact a 6 pound shipment from Kelly Field to Wright Patterson
AFB, as an example, would only cost $16.64, which less than a 40 percent price increase
from the shipment containing only 3 pounds. This means that consolidated shipments of
larger total weights could further optimize total transportation costs.
The primary benefit to be assessed in this cost-benefit analysis is remedied
shortage units which will impact the material availability percentage. Shortage units will
be remedied through the demand aggregation at single and regional ordering sites. The
remedied shortage amount is finalized by applying a coefficient of .9619, as the average
fulfillment rate for the contract in FY19 was 96.19 percent. This refinement accounts for
the fact that although there will be newly generated adequate demand profiles, the
contract likely will not fulfill 100 percent of the requests.
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Summary
This methodology consisting of descriptive data analysis and cost-benefit analysis
steps of alternative project determination, stakeholder identification and determination of
impacts quantitatively depicts the current state of AD WRM contingency pharmaceutical
item shortages. The analysis and results section of this thesis will address the final costbenefit analysis steps of impact prediction, monetization and sensitivity analysis.
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IV. Analysis and Results
Chapter Overview
The analysis and results section of this thesis will finalize the cost-benefit analysis
initiated in the methodology section through a theme of predictive analytics by outlining
cost and benefit predictions, monetization, and sensitivity analysis. Completion of this
analysis and interpretation of results will set up the final recommendation.
Analysis and Results
The results and analysis of this research continues the cost-benefit analysis
through step four of impact prediction and quantification. Completion of this step
facilitates the comparison of various alternatives identified earlier in the methodology.
The below table depicts resulting remedied shortage amounts and shipping weights from
the various alternatives.
Table 1. Impact Predictions
Alternatives
1
Status Quo
2
Single Site Procurement
3
Single Site Procurement
(U.S. Regions)
4
Regional Site
Procurement

Remedied
Shortage
Units

Final
Shipping
Shortage
Weight (Lbs.)
Units

No Change

158,139

141,607

Increased
MAV%

Final
MAV%

No Change

No
Change

80.8

16,532

258,745

21.3

98.0

98,689

59,450

184,462

14.8

92.8

136,210

21,929

247,764

20.4

97.3
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After impact prediction and quantification is complete, the results are monetized
for further comparison. The fifth step of monetization in this cost-benefit analysis will
account for the resulting acquisition and transportation costs, defined earlier, as well as
monetized values for resulting material availability. The monetary value of increases in
material availability were established using the principles of the military production
function, which quantifies militaristic outputs based on monetary inputs (Hartley and
Soloman, 2015).
The resulting benefit ratio was calculated using the total AD WRM programmed
expense of $24.8 million for pharmaceutical procurement. This means that the acquisition
cost of obtaining full material availability has a value of $24.8M based on contractually
negotiated pharmaceutical item prices. Therefore, the value of increased material
availability is calculated to be $248K/percent increase, which was calculated by dividing
the $24.8M in programmed expenses by total fulfillment. With this estimation, and
applications of previously discussed monetization of acquisition and transportation costs,
the final monetization results of the cost-benefit analysis are depicted below.
Table 2. Cost-benefit Analysis Results with Monetization
Alternatives
1
Status Quo
2
Single Site Procurement
3
Single Site Procurement
(U.S. Regions)
4
Regional Site
Procurement

Acquisition Cost

Transportation
Cost

Benefits

Net Results
(Benefits minus
Costs)

No Change

No Change

No Change

No Change

$ (3,544,601)

$ (1,243,016)

$ 5,287,493

$ 499,875

$ (2,038,018)

$ (886,157)

$ 3,684,969

$ 760,793

$ (3,033,908)

$ (9,076)

$ 5,085,973

$ 2,042,988
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It was determined through additional research of the PPV contract that there are
provisions which covers transportation expenses for intra-region shipping, when orders
are placed by a Master Ordering Facility (MOF) within the same region (Defense
Logistics Agency, 2013). This finding was crucial to the estimations and presentations of
transportation costs, as it would eliminate many transportation expenditures when
centralized orders are made intra-region.
Each of the designated ordering hubs, in all alternatives are currently designated
as Master Ordering Facilities (AFMRA/SG4M, 2019). The decrease in additional
transportation costs was accounted for South region orders in alternatives 2 and 3, as the
designated centralized ordering hub of Kelly Field is located in the South Region. Also,
in alternative 4, the only resulting transportation costs captured in this analysis arise from
shipment of items from Travis AFB, in the West region, to the Upper Prairie region
locations.
After monetization is conducted, the sixth step of sensitivity analysis is completed
to evaluate uncertainties or what-if scenarios of the alternative options. As these
pharmaceutical items are procured for uncertain contingency situations, current demand
could either decrease drastically in instances of contingency draw downs, or increase
substantially in situations where new conflicts or emergencies arise. The sensitivity
analysis for this research evaluates shifts in demand through Monte Carlo simulations,
conducted through the Microsoft Visual Basic Application (VBA). This code was
constructed to take small scale simulation efforts conducted on a single item to a platform
such as VBA, which automates the simulations for multiple items simultaneously. The
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VBA code applied in this research simulates changes in demand patterns for all 1124
shortage items assessed in this research. Through base case, maximum case, and
minimum case scenarios validity of the proposed consolidation methods in varying
situations can be tested.
In the simulation, a standard deviation of 10 percent (σ = .1) was applied to the
AD WRM platform’s authorizations for pharmaceutical items to account for possible
variability in future climates. Shifts in these factors were simulated 10,000 times for each
item to allow for determining maximum case (ramp up), and minimum case (draw down)
what-if scenarios.
Table 3. Cost-benefit Analysis Sensitivity Analysis
Alt 4
Simulation
Results
Base Case
Draw Down
(Min Values)
Ramp Up
(Max Values)
Average
(Mode)

Allow
Qty

Final
Shortage
Units
21929
30401

Shipping
Weight
(Lbs)
247764
148501

Increased
MAV%

Final
MAV%

824294
506839

Remedied
Shortage
Units
136210
68970

20.4
16.9

97.3
94.0

1143028

163723

56488

350084

17.7

95.1

821980

115867

43800

248279

17.4

94.6

The outcomes this sensitivity analysis, shown here for alternative four, highlights
that even in instances of varying and uncertain demand, proposed consolidation methods
could be highly beneficial in terms of improving fulfilment. When looking at resulting
costs, there is some uncertainty especially in “ramp up” situations. Due to the
conservative nature of transportation cost estimates used in this research, the calculated
transportation costs reflect single item shipments with an average weight of three pounds.
If optimized shipping cost methods were used, for instance by increasing the weight
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amount of each shipment by sending multiple items in a single shipment, the calculated
value for transportation cost in each ramp up situation would dramatically decrease and
make what-if scenarios more attractive in terms of net results. A full outline of the
simulation results and VBA code are provided in Appendices E and F.
Summary
This analysis and results section is bolstered by the fourth, fifth, and sixth steps of
the cost-benefit analysis process. The fourth step, outlines the resulting impacts being
assessed in this cost-benefit analysis, which are acquisition costs, transportation costs,
and material availability. By making the decision to not undertake any demand
consolidation, the AD WRM program will remain at current material availability levels
for contingency pharmaceuticals. This cost-benefit analysis suggests that if demand
aggregation efforts are undertaken that material availability can increase by a range of
14-21%, depending on which alternative is exercised.
The fifth step of monetization computes the discussed impacts into dollar formats
to allow aid managerial decisions of selecting projects with positive outcomes. Sensitivity
analysis, conducted through Monte Carlo simulations accounting for variability in
demand, shows that these practices of aggregating demand and ordering from a
centralized or regionalized hub are beneficial, even under significant levels of
uncertainty. The last step of the cost-benefit analysis process will be addressed in the
final section of this thesis, the conclusion and recommendation.
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V. Conclusions and Recommendations
Conclusions of Research
This research determined that there are strategic supply chain management
efforts, mainly demand aggregation and centralized procurement, which could be
employed to mitigate the current AFMS contingency pharmaceutical procurement
shortfalls. The costs and benefits of these supply chain principles were determined and all
three proposed alternatives rendered a positive net value. Regardless of decisions made
on which course of action to undertake, be it a full implementation of one of the
identified alternatives or a small scale implementation of aggregated purchasing for
strategically identified items, this research shows the positive effects of practicing
centralized ordering procedures based on demand aggregation of shortage items.
Enacting the principles of centralized ordering procedures for shortage items can
lead to over 20 percent increases in material availability of contingency pharmaceutical
items. However, as pharmaceuticals are only one subset of the medical contingency item
platform, this increased availability of pharmaceutical items is only one part of the
availability issue facing the AFMS in contingency item procurement. To improve the
material availability of the total AD WRM program, additional efforts will need to be
taken to diminish shortages in the supply, equipment and repair item areas of the
program.
Recommendations for Action
The final step of the cost-benefit analysis is to provide a final recommendation.
After determining the flexibility of the PPV contract to utilize Master Ordering Facilities,
39

which can lower intra-region shipping costs, it is recommended to pursue alternative 4
which advocates for regional procurement hubs across the globe. This alternative has the
largest net result as it capitalizes on transportation savings, while only experiencing
minimal decreases to fulfilment levels compared to a single source for procurement of all
items.
For instance alternative 4, which evaluates five regional procurement hubs, would
result in less remedied shortage items than a single procurement site. However, the
transportation savings resulting from intra-region transportation amount to one million
dollars. Leaders would have to make the determination if the resulting unfulfilled units
from alternative 4 is an acceptable shortage when the relevant savings are taken into
account. The use of the military production function, and assertion that each percent
increase in material availability renders $248K value, shows that the small difference in
material availability between alternatives 2 and 4 likely would not be worth the cost of
the increased transportation expenses resulting from the single ordering and distribution
point of alternative 2.
Unless resulting transportation costs of alternative 2 could be drastically
minimized through optimization of shipping processes, alternative 4 is determined to be
the optimal solution. Initial concerns in the conduction of this research was that moving
from a single centralized ordering point to the regional ordering site model would
drastically diminish the aggregated demand profiles, which would lead to decreased
fulfillment levels. However, breaking the demands down by region did not have a drastic
impact on theoretical fulfillment as hypothesized initially.
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Future Research
As contingency pharmaceutical items are only one aspect of the AFMS
contingency item program, future research could be conducted to determine more
effective ordering policies for those non-pharmaceutical items including contingency
medical supplies, equipment, and repair items. Completion of this research would provide
a more robust for necessary actions to fully mitigate all AFMS contingency item
shortages. Future research could also be addressed at a joint, or Defense Health Agency
(DHA), level comprised of aggregated Army, Navy and Air Force data. Future shifts in
military medicine practices, administration, and logistics will see programs moving to a
more joint service perspective under the DHA. This would undoubtedly result in even
larger demand signals, which could further improve DoD material availability of
contingency medical items.
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Appendicies
Appendix A. Allowance Standards (“Allowance Standard Management System,” 2019)
AS
885A

885B

Title
Med Hospital Surgical
Expansion Package-Surg
Equip (HSEP)
Med Hospital Expansion
Package-Equip Inc 1 (HMEP)

Med CT Scan Equipment
885G
Package

UTC
FFEES

AS
902V

FFEEW 902Y
FFHAG 902Z

Allowance Standard List
Title

UTC

AS

Title

UTC

Transport Isolation System IMC

FFTS2

915H

Med Air Transportable Clinic
Equipment

FFLGE

Transport Isolation System SparesRepairs Kit

FFTS5

915I

Medical Theater
Epidemiological Equipment
Pkg

FFHAE

915K

National Airborne Operations
Center (NAOC)

HCBA
C
FFPM4

Transport Isolation Refit Kit

FFTS6

885H Med Ancillary Care Team

FFAN1

903A

Med Deployable Oxygen Package

FF0X2

916E

Med PAM Team ADVON
Equipment (Blk 20)

885I

Med Intensive Care
Equipment

FFCC1

903B

AE Oxygen Support Package

FF0X3

916F

Med PAM Sustainment
Equipment

FFPM5

885J

Med Radiology Equipment
Package

FFRA5

903C

AE Contingency Support Package

FFAM1

917A

Medical Behavioral Health
Equipment

FFBHE

887A

AE Inflight Kits

FFQDM 903F

Electronic Personal Dosimeters

FFPD1

917B

Med Behavioral Health Small
Equip Package

FFBHS

FFQDH 903G

Mobile Oxygen Storage Tanks (MOST)
Package

FFMT1

917C

Med Pediatrics Equipment

FFPE1

FFTC1

Pediatric and Geriatric Support
Package

FFAM3

917D

Med Neurosurgical
Augmentation Equipment

FFNE1

FFQD1 903N

En Route Care Ex Package

FFEC1

917E

Med ENT Augmentation
Equipment

FFET1

AE Operations Team Augmentation
(AEOT AUG) Equipment Package

FFQC2

917F

Med Ophthalmology
Equipment

FFEY1

Patient Loading System

FFPLS

917G

Med Thoracic/Vascular
Equipment

FFGKQ

917H

Med Urology Augmentation
Team Equipment

FFPP1
FFF0E

887B AE Inflight Kit
887C

Resupply

Tactical Critical Care
Evacuation Team

887D Stacking Litter System

903K

887E

Electronic Health Record
(EHR)

FFEHR

887F

Small Aircraft Inflight Kit

FFQD4 903U

Critical Care Air Transport
887H Team (CCATT) Adult
Resupply
887I

Stacking Litter Adapters

FFCCB

Critical Care Air Transport
Team (CCATT) Adult

CCATT Pediatric
887O
Augmentation

903V

AES AE Liaison TM Equip Pckg

FFQL1

AE Operations Tm Equip Pkg.

FFQN1

917I

Med Dental Equipment
Package

903Z

AE Command Sq Equip Pkg

FFQC1

917J

High Altitude Air Drop Mission
FFQB1
Support

FFCC4

904E

Deployable Maintenance Equipment
Package

FFBM1

917L

Med OB/GYN Equipment

FFGY1

FFCC2

904F

En Route Patient Staging System
(ERPSS) 10

FFPS1

917P

Med Oral Surgery Equipment

FFMA1

FFPS2

917Q

Med Optometry Augmentation
FFD01
Team Equipment

FFQD2 903Y

887M Portable Ultra Sound System FFCC5
887N

903O

Patient Movement Items

FFQP3

904G

En Route Patient Staging System
(ERPSS) Equipment PKG - 50

Deployable Patient
887Q Movement Item Tracking
System (PMITS)

FFQP4

904H

En Route Patient Staging System
(ERPSS) Expendable PKG - 50

FFPS3

917R

Med EMEDS HA Augmentation
FFP0E
Tm Equipment

887R Patient Isolation Unit

887P

FFP1U

904I

En Route Patient Staging System
(ERPSS) Facility PKG - 50 Bed

FFPS4

920A

EMERGENCY CRASH CART

893A

Blood Donor Center (WHMC) 1FBLD

904J

En Route Patient Staging System
(ERPSS) Support Package

FFPS7

937N

Med Ambulance Augmentation
FFAMB
Package

893B

CONUS Blood Donor Center
(600 Pint)

2FBLD

904K

En Route Patient Staging System
(ERPSS) Resupply

FFPS8

938B

Med EMEDS +10/AFTH-Equip
Inc 2

FFEE2

893C

Med Expeditionary Blood
Support Center Equipment

FFLB1

905A

Medical Support Package

FFSR1

938C

Med EMEDS +25/AFTH-Equip
Inc 3

FFEE3

893E

Blood Processing Laboratory
(ASWBPL)- McGuire

3FBLD

912C

SOF Surgical Primary Response
Equipment

FFQEF

938D

Med EMEDS Basic Resupply

FFEE4

893F

Frozen Blood Program
Equipment

FZNBP

912D

SOF Surgical Electrical Equipment
Augmentation

FFQEE

938E

Med EMEDS +10/AFTH
Resupply

FFEE5

893I

Blood Processing Laboratory
(ASWBPL) - Travis

4FBLD

912G

SOF MED Oxygen

FFQEU

938F

Med EMEDS +25/AFTH
Resupply

FFEE6

893J

Med Expeditionary Blood
Transhipment System
Equipment

FFBE1

912H

SOF Base Medical Support - Air Trans
Treatment Unit (ATTU)

FFQEL

938G

Med Mobile Field Surgical
Team Equipment (MFST)

FFMF1

902A

Med Patient
Decontamination Equipment

FFGLC

912K

SOF Medical Element Augmentation
Equipment

FFQEG 938J

Med Critical Care Equipment

FFEPE

902B

Med BEE NBC Team
Equipment

FFGL7

912L

Casualty Evacuation Module

FFQEN

938M

Med Water Distribution
System WDS

FFWD
S

902C

Med Biological Augmentation
FFBA1
Equipment

912M SOF Surgical Sustainment Equipment

FFQES

938P

Med EMEDS HRT Equipment
Inc 1

FFHR1

902G

Med AFRAT-Rad/Nuc Crisis
ADVON Team

912N

SOF Critical Care Evac Primary
Response Equipment

FFQEB

938Q

Ground Surgical EQ

FFGS1
FFCPS

Med AFRAT RAD/NUC
902H
Surveillance Tm

FFRN1

CCART

FFRN2

912O

SOF Rapid Response Deployment Kit

FFQEM 948A

Med CP Medical Tent With
Airlock

902J

Med Infectious Disease
Team Equipment

FFHAF

912Q

SOF Critical Care Evac Equipment

FFQEC

Med CP Water Distribution
System Without Airlock

FFCPW

902K

Med Contagious Casualty
Management - CCM

FFCCM 912R

SOF Extended Reach Medical
Equipment

FFQED 948F

Med CP Hospital Surgical
Expansion Package

FFCPE

902L

Med AFRAT RAD/NUC
Surveillance Aug Equipment

FFRND 912S

SOF PEDS

FFQEJ

Med CP Hospital Medical
Expansion Package

FFCPF

902M

Med AFRAT RAD/NUC
Laboratory Team

FFRN4

912W SOF Irregular Warfare

FFQEW 948H

MED CP ONE TENT
W/AIRLOCK

FFCP1

902N

Med AFRAT RAD/NUC
Laboratory Aug Equipment

FFRNB

913J

Pararescue Medical Support Kits

81SBD 948I

MED CP 4 TENT
W/AIRLK/CPEL

FFCP2

902O

Med AFRAT RAD/NUC
Dosimetry Team

FFRN6

913K

Pararescue Medical Support Accessory
Kits

81SLG

MED CP 3 TENT W/AIRLOCK

FFCP3

902P

Med AFRAT RAD/NUC
Dosimetry Aug Equipment

FFRNC

913N

NASA Assemblage

NASA1 948K

MED CP 3 TENT CPEL

FFCP4

902U

Transport Isolation System
(TIS ) AM and IME

FFTS1

915G

Medical Global Reach Laydown Team

FFGR1

MED CP ONE TENT

FFCP5
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948E

948G

948J

948L

Appendix B. Procurement Process (HQ USAF/SG, 2013), (AFMRA/SG4M, 2019)
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Appendix C. Stock Record Account Number Designations (JMAR, 2019)
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Appendix D. Contingency Pharmaceutical Item Shortages (JMAR, 2019)
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Appendix E. Simulation Results (JMAR, 2019)
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Appendix F. VBA Code
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